The Competitive Interplay between Allosteric HIV-1 Integrase Inhibitor BI/D and LEDGF/p75 during the Early Stage of HIV-1 Replication Adversely Affects Inhibitor Potency
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Allosteric HIV-1 integrase inhibitors (ALLINIs) have recently emerged as a promising class of antiretroviral agents and are currently in clinical trials. In infected cells, ALLINIs potently inhibit viral replication by impairing virus particle maturation but surprisingly exhibit a reduced EC50 for inhibiting HIV-1 integration in target cells. To better understand the reduced antiviral activity of ALLINIs during the early stage of HIV-1 replication, we investigated the competitive interplay between a potent representative ALLINI, BI/D, and LEDGF/p75 with HIV-1 integrase. While the principal binding sites of BI/D and LEDGF/p75 overlap at the integrase catalytic core domain dimer interface, we show that the inhibitor and the cellular cofactor induce markedly different multimerization patterns of full-length integrase. LEDGF/p75 stabilizes an integrase tetramer through the additional interactions with the integrase N-terminal domain, whereas BI/D induces protein-protein interactions in C-terminal segments that lead to aberrant, higher-order integrase multimerization. We demonstrate that LEDGF/p75 binds HIV-1 integrase with significantly higher affinity than BI/D and that the cellular protein is able to reverse the inhibitor induced aberrant, higher-order integrase multimerization in a dose-dependent manner in vitro. Consistent with these observations, alterations of the cellular levels of LEDGF/p75 markedly affected BI/D EC50 values during the early steps of HIV-1 replication. Furthermore, genome-wide sequencing of HIV-1 integration sites in infected cells demonstrate that LEDGF/p75-dependent integration site selection is adversely affected by BI/D treatment. Taken together, our studies elucidate structural and mechanistic details of the interplay between LEDGF/p75 and BI/D during the early stage of HIV-1 replication.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consistent with the known role of LEDGF/p75 in HIV-1 integration targeting, genic integration targeting during HIV-1 ingress was suppressed by ALLINIs177,184,185.”
From Structure and function of retroviral integrase (2022) · cites this paper as [184]
Citations
Cites
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
Berne, B. J., & Pecora, R. (1976) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,856
BioNumbers—the database of key numbers in molecular and cell biology
Milo, R., Jorgensen, P., Moran, U., Weber, G., & Springer, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp889 · Cited by 1,055 · cited 1×
“All numbers taken from BioNumbers (51).”
HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells
Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., & Debyser, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209278200 · Cited by 704
A role for LEDGF/p75 in targeting HIV DNA integration
Ciuffi, A., Llano, M., Poeschla, E., Hoffmann, C., Leipzig, J., Shinn, P., Ecker, J. R., & Bushman, F. (2005) · Nature Medicine · doi:10.1038/nm1329 · Cited by 658 · cited 1×
“additional viral and cellular proteins, to active genes during integration (2-6).”
Self-citationAn essential role for LEDGF/p75 in HIV integration
Llano, M., Saenz, D. T., Meehan, A., Wongthida, P., Peretz, M., Walker, W. H., Teo, W., & Poeschla, E. M. (2006) · Science · doi:10.1126/science.1132319 · Cited by 537 · cited 1×
“additional viral and cellular proteins, to active genes during integration (2-6).”
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479 · cited 1×
“LEDGF/IBD binding to the IN CCD-CCD dimer interface (22, 24, 26, 28-31).”
Shun, M.-C., Raghavendra, N. K., Vandegraaff, N., Daigle, J. E., Hughes, S., Kellam, P., Cherepanov, P., & Engelman, A. (2007) · Genes & Development · doi:10.1101/gad.1565107 · Cited by 467 · cited 1×
“additional viral and cellular proteins, to active genes during integration (2-6).”
Self-citationThe structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424 · cited 1×
“bind viral DNA and contribute to the functional tetramerization of IN (reviewed in (9-14)).”
Self-citationStructural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408 · cited 4×
“same pocket at the IN CCD dimer interface (17, 28), our HDX experiments have”
InfluentialSelf-citationPradeepa, M. M., Sutherland, H. G., Ule, J., Grimes, G. R., & Bickmore, W. A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002717 · Cited by 349
Research works printed but not linked: 1
- 10.1074/jbc.M112.354373 · DOI · Paper page
Cited by
Structural and mechanistic bases for a potent HIV-1 capsid inhibitor
Bester, S. M., Wei, G., Zhao, H., Adu-Ampratwum, D., Iqbal, N., Courouble, V. V., Francis, A. C., Annamalai, A. S., Singh, P. K., Shkriabai, N., et al. (2020) · Science · doi:10.1126/science.abb4808 · Cited by 239
Self-citationCapsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration
Achuthan, V., Perreira, J. M., Sowd, G. A., Puray-Chavez, M., McDougall, W. M., Paulucci-Holthauzen, A., Wu, X., Fadel, H. J., Poeschla, E. M., Multani, A. S., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.08.002 · Cited by 205
“In lieu of PSIP1 knockout, cells were treated at the time of infection with the allosteric IN inhibitor BI-D, which, under these conditions, competes with IN-LEDGF/p75 binding and inhibits HIV-1 integration (Feng et al., 2016; Jurado et al., 2013).”
MethodSelf-citationStructure and function of retroviral integrase
Maertens, G. N., Engelman, A. N., & Cherepanov, P. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00586-9 · Cited by 124
Self-citationVranckx, L. S., Demeulemeester, J., Saleh, S., Boll, A., Vansant, G., Schrijvers, R., Weydert, C., Battivelli, E., Verdin, E., Cereseto, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.039 · Cited by 113
“In any case LEDGIN treatment results in a steep dose-dependent inhibition of viral replication in cell culture, supporting their clinical development (Fader et al., 2014; Fenwick et al., 2014).”
BackgroundCellular and molecular mechanisms of HIV-1 integration targeting
Engelman, A., & Singh, P. K. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2772-5 · Cited by 113
“ALLINI binding induces the formation of large integrase aggregates [191, 192, 202] through the bridging of neighboring protein molecules [203, 204].”
BackgroundSelf-citationMultifaceted HIV integrase functionalities and therapeutic strategies for their inhibition
Engelman, A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.006901 · Cited by 87
“Instead of being the antiviral target, engagement of IN by LEDGF/p75 during the early phase of HIV-1 infection protects the virus from the inhibitory action of the compounds (221).”
BackgroundSelf-citationMass Spectrometry-Based Structural Virology
Wörner, T. P., Shamorkina, T. M., Snijder, J., & Heck, A. J. R. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04339 · Cited by 63
HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
Koneru, P. C., Francis, A. C., Deng, N., Rebensburg, S. V., Hoyte, A. C., Lindenberger, J., Adu-Ampratwum, D., Larue, R. C., Wempe, M. F., Engelman, A. N., et al. (2019) · eLife · doi:10.7554/elife.46344 · Cited by 49
“Mass spectrometry-based protein foot-printing experiments (Feng et al., 2016; Shkriabai et al., 2014) with full-length IN identified that in addition to the CCD, the CTD plays a critical role for inhibitor induced hyper-multimerization of IN.”
BackgroundSelf-citationBonnard, D., Le Rouzic, E., Eiler, S., Amadori, C., Orlov, I., Bruneau, J.-M., Brias, J., Barbion, J., Chevreuil, F., Spehner, D., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816793 · Cited by 42
“It was also reported that modulating LEDGF/p75 levels in target cells (by knockout or overexpression) determines INLAI BI-D potency at integration (37).”
BackgroundStrategies for Targeting Retroviral Integration for Safer Gene Therapy: Advances and Challenges
Yoder, K. E., Rabe, A. J., Fishel, R. A., & Larue, R. C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.662331 · Cited by 41
“Treatment with one such drug, BI-D, decreased HIV-1 integration in genes from 86.4% to 67.9% (Feng et al., 2016).”
BackgroundInfluentialSelf-citationDeng, N., Hoyte, A., Mansour, Y. E., Mohamed, M. S., Fuchs, J. R., Engelman, A. N., Kvaratskhelia, M., & Levy, R. (2016) · Protein Science · doi:10.1002/pro.2997 · Cited by 36
“This view is consistent with a recent report showing that LEDGF/p75 binding is able to inhibit ALLINI-induced multimerization.(24) Presum-”
ResultSelf-citationGS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture
Bruggemans, A., Vansant, G., Balakrishnan, M., Mitchell, M. L., Cai, R., Christ, F., & Debyser, Z. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02328-20 · Cited by 35
“CX14442 (20, 51), CX05045 (51), and the BI/D compound (54).”
BackgroundSynthesis and Evaluation of Aryl Quinolines as HIV-1 Integrase Multimerization Inhibitors
Jentsch, N. G., Hart, A. P., Hume, J. D., Sun, J., McNeely, K. A., Lama, C., Pigza, J. A., Donahue, M. G., & Kessl, J. J. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00269 · Cited by 32
Self-citationPatel, D., Antwi, J., Koneru, P. C., Serrao, E., Forli, S., Kessl, J. J., Feng, L., Deng, N., Levy, R. M., Fuchs, J. R., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.753384 · Cited by 30
“31 kcal/mol per non-hydrogen atom for direct binding of a highly potent representative ALLINI, BI-D, to IN (42).”
BackgroundSelf-citationStructure and Dynamics of the Liver Receptor Homolog 1–PGC1α Complex
Mays, S. G., Okafor, C. D., Tuntland, M. L., Whitby, R. J., Dharmarajan, V., Stec, J., Griffin, P. R., & Ortlund, E. A. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108514 · Cited by 28
“Solution-phase amide HDX experiments were carried out as described previously (Feng et al., 2016) using a fully automated system, in which sample handling was done using CTC HTS Twin PAL robots (LEAP Technologies, Carrboro, NC) housed inside a 4°C cabinet.”
MethodSelf-citationStructural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir
Briganti, L., Annamalai, A. S., Bester, S. M., Wei, G., Andino-Moncada, J. R., Singh, S. P., Kleinpeter, A. B., Tripathi, M., Nguyen, B., Radhakrishnan, R., et al. (2025) · mBio · doi:10.1128/mbio.03613-24 · Cited by 29
“Integration site libraries were prepared by performing ligation-mediated PCR (LM-PCR) as described previously with minor modifications (13, 62).”
Self-citationGupta, K., Allen, A., Giraldo, C., Eilers, G., Sharp, R., Hwang, Y., Murali, H., Cruz, K., Janmey, P., Bushman, F., et al. (2021) · Structure · doi:10.1016/j.str.2020.12.001 · Cited by 19
“SANS profiles for 100 μM INF185H or 100 μM co-expressed INF185H•LEDGF(IBD) in the presence of 100 μM BI-224436 (F) or 100 μM BI-D (G).”
BackgroundInfluentialSelf-citationThe Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function
Singer, M. R., Dinh, T., Levintov, L., Annamalai, A. S., Rey, J. S., Briganti, L., Cook, N., Pye, V. E., Taylor, I. A., Kim, K., et al. (2023) · mBio · doi:10.1128/mbio.03560-22 · Cited by 21
Self-citationBiological and Structural Analyses of New Potent Allosteric Inhibitors of HIV-1 Integrase
Bonnard, D., Rouzic, E. L., Singer, M. R., Yu, Z., Strat, F. L., Batisse, C., Batisse, J., Amadori, C., Chasset, S., Pye, V. E., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-23 · Cited by 17
Jing, T., Shan, Z., Dinh, T., Biswas, A., Jang, S., Greenwood, J., Li, M., Zhang, Z., Gray, G., Shin, H. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64479-8 · Cited by 17
Self-citationBurlein, C., Wang, C., Xu, M., Bhatt, T., Stahlhut, M. W., Ou, Y., Adam, G. C., Heath, J., Klein, D. J., Sanders, J. M., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00550 · Cited by 14
Ohata, Y., Tomonaga, M., Watanabe, Y., Tomura, K., Kimura, K., Akaki, T., Adachi, K., Kodama, E. N., Matsuzaki, Y., & Hayashi, H. (2022) · Journal of Virology · doi:10.1128/jvi.01843-21 · Cited by 14
“Furthermore, LEDGF/p75 affects the integration site selection (10, 11) and mediates”
BackgroundSingh, P., Li, W., Bedwell, G., Fadel, H., Poeschla, E., & Engelman, A. (2022) · Viruses · doi:10.3390/v14091883 · Cited by 13
“We have utilized BI-D, which is a prototypical quinoline ALLINI [44,61] previously shown to reduce genic HIV-1 integration targeting in HEK293T cells [55].”
MethodSelf-citationVirus–Host Interactions in Retrovirus Integration
Engelman, A. N., & Maertens, G. N. (2018) · Retrovirus-Cell Interactions · doi:10.1016/b978-0-12-811185-7.00004-2 · Cited by 12
Self-citationDinh, T., Tber, Z., Rey, J. S., Mengshetti, S., Annamalai, A. S., Haney, R., Briganti, L., Amblard, F., Fuchs, J. R., Cherepanov, P., et al. (2024) · mBio · doi:10.1128/mbio.00465-24 · Cited by 14
Self-citationAgharbaoui, F. E., Hoyte, A. C., Ferro, S., Gitto, R., Buemi, M. R., Fuchs, J. R., Kvaratskhelia, M., & Luca, L. D. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.07.077 · Cited by 11
“In the virions, where due to the lack of competing LEDGF/p75 binding to the IN dimer, ALLINIs potently induce aberrant IN multimerization and result in eccentric, non-infectious virions; whereas during the early stage of HIV-1 replication LEDGF/p75 effectively competes with ALLINI binding to IN and reduces the inhibit…”
BackgroundSelf-citationIdentification and Optimization of a Novel HIV-1 Integrase Inhibitor
Adu‐Ampratwum, D., Pan, Y., Koneru, P. C., Antwi, J., Hoyte, A. C., Kessl, J. J., Griffin, P. R., Kvaratskhelia, M., Fuchs, J. R., & Larue, R. C. (2022) · ACS Omega · doi:10.1021/acsomega.1c06378 · Cited by 8
Self-citationAnti-DFS70 autoantibodies in HIV-1-positive individuals
Pérez, M. D., & Azoulay, D. (2018) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000495 · Cited by 7
Aknin, C., Smith, E. A., Marchand, C., Andréola, M., Pommier, Y. G., & Métifiot, M. (2019) · Molecules · doi:10.3390/molecules24203675 · Cited by 7
“These inhibitors have a complex mechanism of action, and they have been shown to be very useful tools to understand the role of IN during virus assembly and morphogenesis [22,23].”
BackgroundFluorescence, Circular Dichroism and Mass Spectrometry as Tools to Study Virus Structure
Neira, J. L. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-65187-8_6 · Cited by 2
Synthesis and Antiviral Activity of Some 1H-Pyrrolo[3,2-b]pyridin-6-yl)acetic Acid Derivatives
Yoon, H. L., Nam, H.-J., Kim, U.-I., Kim, K., & Kim, B. J. (2017) · Asian Journal of Chemistry · doi:10.14233/ajchem.2017.20372 · Cited by 1
Retroviral Vectors for Gene Therapy of Monogenic Diseases
Yoder, K. E., Rabe, A. J., & Larue, R. C. (2022) · Springer eBooks · doi:10.1007/978-3-030-93333-3_7 · Cited by 1
Self-citationIdentification of specific phylogenetic properties of HIV-1 M and O integrases
Toccafondi, E. (2022) · theses.fr (ABES) · doi:10.70675/2facab6ezc20az472dz8350z9fb6e718e1d4 · Cited by 1
Amadori, C. (2016) · theses.fr (ABES) · doi:10.70675/2da75a32z2820z4ceaz8909zee47e88e36ee
“De plus LEDGF ayant une meilleure affinité que les INLAIs pour son site de fixation sur l’IN, le cofacteur cellulaire peut agir comme un compétiteur du BI-D en empêchant ou en inversant l’oligomérisation anormale de l’IN induite par ces antirétroviraux [358].”
BackgroundRabe, A. J., Russo, J. A., Larue, R. C., & Yoder, K. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.19.508505
“Recombinant HIV-1 and LEDGF/p75 were purified as previously described [20-22].”
MethodSelf-citationHIV-1 Integrase During the Time: History of Drugs and Effort for the New Inhibitors’ Identification
Esposito, F., Saccoliti, F., Patacchini, E., & Santo, R. D. (2026) · Topics in medicinal chemistry · doi:10.1007/7355_2026_180
The LEDGIN GS-9822 inhibits HIV-2 infection and enhances HIV-2 latency
Bruggemans, A., Vansant, G., Pellaers, E., de Velde, P. V., Christ, F., & Debyser, Z. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01699-25
BindingDB (2020) · UC San Diego · doi:10.7270/q2pc352q
Metadata
- Authors
- Feng, L., Dharmarajan, V., Serrao, E., Hoyte, A., Larue, R. C., Slaughter, A., Sharma, A., Plumb, M. R., Kessl, J. J., Fuchs, J. R., Bushman, F. D., Engelman, A. N., Griffin, P. R., & Kvaratskhelia, M.
- Affiliations
- The Ohio State University (US)
- Scripps Research Institute (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Corresponding author
- Kvaratskhelia, Mamuka
- ORCID
- Venue
- ACS Chemical Biology
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-02
- Volume
- 11
- Issue
- 5
- Pages
- 1313-1321
- ISSN
- 1554-8929 (ISSN-L)
- 1554-8937
- PMC
- PMC4874862
- OpenAlex
- W2284278883
- Cited by
- 37
- References
- 51
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 4
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (AI052845, AI110270, AI110310)
- National Institute of General Medical Sciences (GM103368)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- LEDGF/p75, HIV-1 integrase, integrase multimerization
- MeSH terms
- Allosteric Regulation, Humans, Virus Replication, HIV-1, HIV Infections, HIV Integrase, HIV Integrase Inhibitors, Intercellular Signaling Peptides and Proteins, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.